NIKKEI 225
26,107.65 -315.82 (-1.20%) HANG SENG
21,586.66 -266.41 (-1.22%) CRUDE OIL
97.80 -1.70 (-1.71%) GOLD FUTURES
1,736.80 -27.10 (-1.54%) DOW
30,870.46 -97.36 (-0.31%) BTC-GBP
16,974.68 +365.51 (+2.20%)
CVAC Jan 2023 110.000 call
| Previous close | 1.5000 |
| Open | 1.5000 |
| Bid | 0.3000 |
| Ask | 1.3000 |
| Strike | 110.00 |
| Expiry date | 2023-01-20 |
| Day's range | 1.5000 - 1.5000 |
| Contract range | N/A |
| Volume | |
| Open interest | 25 |
- The Telegraph
German drugmaker accused of stealing Covid vaccine technology
The team behind Britain’s most-used Covid booster vaccine is being sued by a German pharmaceutical firm which has accused it of stealing the technology behind the jab.
- Reuters
CureVac files patent lawsuit in Germany against BioNTech over mRNA technology
BERLIN (Reuters) -CureVac has filed a patent lawsuit in Germany against BioNTech over its use of mRNA technology, marking one of the first known cases of a company going to court amid the fierce competition to develop a vaccine against the coronavirus. The German-based biotech company is seeking "fair compensation" from BioNTech and two subsidiaries for infringement of its intellectual property rights, it said on Tuesday. When asked in a media call, Chief Executive Franz-Werner Haas did not rule out further legal action against BioNTech partner Pfizer or mRNA vaccine maker Moderna.
- EQS Group
CureVac Files Patent Infringement Lawsuit in Germany Against BioNTech
Issuer: CureVac / Key word(s): Legal Matter05.07.2022 / 13:00 The issuer is solely responsible for the content of this announcement.CureVac Files Patent Infringement Lawsuit in Germany Against BioNTech TÜBINGEN, Germany/ Boston, USA – July 5, 2022 – CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”) today announced that it has moved to assert its intellectual property rights, accumulated
